Novo Nordisk announced promising new data for its next-generation obesity drug, CagriSema, which demonstrated an average weight loss of 25% among adult women after 68 weeks in a late-stage trial analysis. This experimental injection combines semaglutide—the active ingredient in Novo's blockbuster obesity treatment Wegovy—with cagrilintide, targeting an additional hormone pathway to potentially boost weight loss effectiveness beyond current GLP-1 therapies. While the company emphasized the need for further validation, the results mark a significant step toward offering enhanced obesity treatments.

In the analysis involving about 2,300 women with overweight or obesity, participants receiving CagriSema lost 25% of their body weight on average, compared to a 3% loss in the placebo group, assuming uninterrupted treatment. Additional research categorized roughly 1,900 women by menopause status, revealing weight losses of 26.7%, 24.8%, and 23.1% in premenopausal, perimenopausal, and postmenopausal women, respectively, versus about 2% in placebo counterparts. The drug also produced reductions in abdominal fat across all menopause stages, measured by waist circumference.

Novo's focus on women is significant given the common weight gain associated with menopause, driven by hormonal changes like declining estrogen. More than 86 million U.S. women aged 40 and older face challenges maintaining or losing weight during perimenopause and beyond, underscoring the potential impact of treatments like CagriSema across the reproductive lifespan. Michelle Skinner Moore, Novo's interim head of clinical development, highlighted the importance of addressing obesity in women throughout menopause with such investigational medications.

Despite these positive findings, investor reaction to CagriSema has been muted, partly due to previous late-stage results that fell below market expectations. Nonetheless, Novo remains confident in the drug’s distinct profile and market potential, with analysts projecting obesity-specific sales to reach nearly $12 billion by 2028. The company plans to launch CagriSema early next year, positioning it as a potential new leader in obesity treatment amid competition from Eli Lilly and others developing drugs that target the amylin hormone pathway alongside GLP-1.